Vivace Therapeutics announces dosing of first cohort of patients with its first-in-class TEAD inhibitor

Retrieved on: 2021-05-04 15:56:15

Tags for this article:

Click the tags to see associated articles and topics

Vivace Therapeutics announces dosing of first cohort of patients with its first-in-class TEAD inhibitor. View article details on hiswai:

Excerpt

... including Canaan Partners, WuXi Healthcare Ventures, Cenova Capital, Sequoia Capital China, Boxer Capital and RA Capital Mangement.

Article found on: www.prnewswire.com